Eli Lilly CEO Taurel: Icos Deal Is Fair

Thursday, 7 Dec 2006 | 9:02 AM ET

In a "First on CNBC-TV" Eli Lilly CEO and Chairman Sidney Taurel sat down with Mike Huckman on "Squawk Box" to talk about the company--as the it meets with analysts today and issued new guidance.

The pharmaceutical company says sales growth for 2007 will be in the low end of the 7-9% range--versus 6% for 2006. It also said its 2007 EPS will be $3.25 to $3.35---but that comes with a 10 cent hit from its acquisition of Icos --the partner Lilly had for the male erectile dysfunction drug Cialis.

Huckman asked Taurel about that acquisition--stating that the Institute of Shareholder Services issued a report saying the deal was undervalued. Taurel replied by saying he felt it was a fair deal and that the price of $32 a share was agreed upon by both companies. Icos shares have been trading lately at around $33 a share.

Taurel also said that the failure of Pfizer's experimental anti-cholesterol drug torcetrapib--shows that the industry is risky at times. He said he believes Pfizer will NOT buy Amylin --Lilly's partner in making a diabetes drug.

Lilly CEO
Eli Lilly is out with guidance this morning. Insight with Sydney Taurel, Eli Lilly Chairman & CEO and CNBC's Mike Huckman
  Price   Change %Change


Contact Squawk Box


    Get the best of CNBC in your inbox

    › Learn More
  • Showtimes

    Weekdays 6a ET
    Weekdays 13:00 CET
    Weekdays 18:00 SIN/HK
    Weekdays 20:00 SYD
    New Zealand
    Weekdays 22:00 NZ
  • Joe Kernen is co-anchor of "Squawk Box," CNBC's signature morning program.

  • Becky Quick is co-anchor of "Squawk Box," CNBC's signature morning program. She's also a columnist for Fortune.

  • Andrew Ross Sorkin is a co-anchor of "Squawk Box," a financial columnist for "The New York Times" and the editor-at-large of NYT's DealBook.